Tempus AI, Inc. Q1 2026 Earnings Call Summary

Tempus AI, Inc. recently held its Q1 2026 Earnings Call, where they highlighted several key performance drivers that have contributed to their strategic growth.

One of the standout factors was the company’s revenue growth of 36%, primarily driven by a 40.5% surge in the data applications business. This growth was fueled by the Insights segment’s data licensing and modeling capabilities. Management credited the 28% unit growth in oncology to high attach rates for transcriptomic algorithms that aid physicians in real-time decision-making.

Tempus AI, Inc. is also transitioning from simple data licensing to strategic AI collaboration, with partners increasingly building proprietary foundation models on the company’s 500-petabyte database. The shift in pharma relationships is moving towards large-scale, multi-year strategic collaborations exceeding $100 million in total contract value.

While the hereditary business experienced a temporary slowdown due to challenging year-over-year comparisons, management expects a return to mid-teens growth in the second half of 2026. Operational efficiency is also improving through a diversified portfolio where high-margin data revenue offsets the costs of scaling diagnostic volume.

Looking ahead, the company raised its full-year 2026 revenue guidance to a range of $1.59 billion to $1.60 billion, supported by a strong pipeline of data and applications. They also project a $500 incremental lift in diagnostic average selling price (ASP) over the next one to two years. Tempus AI, Inc. aims to maintain a 25% top-line compound annual growth rate over the next three years, driven by volume expansion and reimbursement tailwinds.

In terms of operational risks and structural updates, the company is awaiting an FDA decision on an amendment for the XT assay to cover tumor-only cases. This decision is crucial for accelerating the migration to higher-priced ADLT versions. Q1 cash flow from operations was impacted by seasonal bonus payouts and timing of payables, which is expected to normalize in Q2. Management reiterated that they have no need for additional financing, with a clear path to positive adjusted EBITDA of $65 million for the year.

In conclusion, Tempus AI, Inc. is strategically positioned for growth with a focus on data applications, AI collaboration, and strategic partnerships in the pharma industry. Their strong performance drivers and outlook for continued growth make them a key player in the healthcare technology sector.